BioSpace News Archive

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, reported financial results and business highlights for the third quarter ended September 30, 2022.

Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, reported financial results for the quarter ended September 30, 2022, and provided operational updates.

UCB announced the first presentation of long-term, 52-week data from three Phase 3 studies evaluating the efficacy and safety of bimekizumab in adults with active psoriatic arthritis who were biologic-naïve, in adults with active non-radiographic axial spondyloarthritis, and in adults with active ankylosing spondylitis.

BioLineRx Ltd. announced that the U.S. Food and Drug Administration has accepted for review and filed the Company’s New Drug Application for APHEXDA® in stem cell mobilization for autologous transplantation in multiple myeloma patients.

ESSA Pharma Inc. today announced that the Company will be participating in two upcoming investor conferences.

Orthofix Medical Inc. today announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will participate in a fireside chat during the upcoming Stifel 2022 Healthcare investor conference on Wednesday, November 16, 2022 at 8:00 a.m. ET.

Parthenon Therapeutics and ImaginAb Inc. today announced that the companies have entered into a multi-year, non-exclusive license and supply agreement.

BeiGene Announces Brazil Approvals for BRUKINSA ® As a Treatment for Rare Blood Cancers.

Silence Therapeutics plc today reported its financial results for the third quarter ended September 30, 2022 and reviewed recent business highlights.

Century Therapeutics today reported financial results and business highlights for the third quarter ended September 30, 2022.